Zimmer Biomet price target lowered to $112 from $125 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $125 and keeps an Outperform rating on the shares. The company delivered Q1 results that modestly beat consensus on sales and earnings, while the management reiterated 2025 organic sales growth, but lowered EPS guidance to account for the Paragon 28 acquisition and $60-$80M in tariffs that are fully offset by FX at this time, the analyst tells investors in a research note. The stock’s double-digit decline is due to multiple factors, including U.S. knee growth, Q2 commentary, second-half growth weighting, Paragon 28-related dilution, and tariffs, the firm adds.